PSNL

Personalis Inc

PSNL, USA

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company has strategic collaboration with Tempus AI, Inc. to bring ultra-sensitive cancer recurrence testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.

https://www.personalis.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PSNL
stock
PSNL

Personalis (Nasdaq: PSNL) Cell study follows 431 lung cancer patients with NeXT Personal Stock Titan

Read more →
PSNL
stock
PSNL

Why Analysts See Personalis Story Shifting With Medicare Tailwinds And Biopharma Headwinds Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$11

Analyst Picks

Strong Buy

4

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.54

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-12.63 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-8.92 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-161.64 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.42

Low 1

High 0.3

Investors

* Institutions hold a combined 91.35% of the total shares of Personalis Inc

1.

Merck & Co Inc

(15.8383%)

since

2025/06/30

2.

Lightspeed Management Co LLC

(9.2028%)

since

2025/06/30

3.

ARK Genomic Revolution ETF

(9.1005%)

since

2025/08/28

4.

ARK Investment Management LLC

(8.0155%)

since

2025/06/30

5.

ARK Genomic Revolution

(7.8418%)

since

2025/06/30

6.

BlackRock Inc

(5.8685%)

since

2025/06/30

7.

AIGH Capital Management, LLC

(4.1995%)

since

2025/06/30

8.

Vanguard Group Inc

(3.5376%)

since

2025/06/30

9.

Aberdeen Group PLC

(1.9842%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(1.9667%)

since

2025/07/31

11.

Blue Water Life Science Advisors, LLC

(1.8903%)

since

2025/06/30

12.

Geode Capital Management, LLC

(1.54%)

since

2025/06/30

13.

T. Rowe Price Investment Management,Inc.

(1.4259%)

since

2025/06/30

14.

iShares Russell 2000 ETF

(1.3961%)

since

2025/08/31

15.

abrdn Healthcare Investors

(1.3279%)

since

2025/08/31

16.

Millennium Management LLC

(1.23%)

since

2025/06/30

17.

abrdn Life Sciences Investors

(1.1411%)

since

2025/08/31

18.

Dimensional Fund Advisors, Inc.

(0.8851%)

since

2025/06/30

19.

T. Rowe Price Small-Cap Value

(0.8616%)

since

2025/07/31

20.

T. Rowe Price Small-Cap Stock

(0.8228%)

since

2025/07/31

21.

State Street Corp

(0.7754%)

since

2025/06/30

22.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7579%)

since

2025/07/31

23.

Kennedy Capital Management Inc

(0.7368%)

since

2025/06/30

24.

Sumitomo Mitsui Trust Group Inc

(0.7222%)

since

2025/06/30

25.

Nuveen, LLC

(0.7167%)

since

2025/06/30

26.

Amova Asset Management Americas, Inc

(0.7153%)

since

2025/06/30

27.

Morgan Stanley - Brokerage Accounts

(0.7064%)

since

2025/06/30

28.

BlackRock Advantage Small Cap Core Instl

(0.6912%)

since

2025/07/31

29.

Renaissance Technologies Corp

(0.6352%)

since

2025/06/30

30.

Kennedy Micro Cap

(0.577%)

since

2025/06/30

31.

Fidelity Small Cap Index

(0.5668%)

since

2025/06/30

32.

State Treasurer State Of Michigan

(0.5568%)

since

2025/06/30

33.

T. Rowe Price U.S. SC Value Eq Tr-D

(0.5247%)

since

2025/06/30

34.

iShares Russell 2000 Value ETF

(0.4905%)

since

2025/08/31

35.

T. Rowe Price Instl Small-Cap Stock

(0.4166%)

since

2025/07/31

36.

Fidelity Extended Market Index

(0.3783%)

since

2025/07/31

37.

Nuveen Quant Small Cap Equity R6

(0.3603%)

since

2025/07/31

38.

iShares Biotechnology ETF

(0.3513%)

since

2025/08/31

39.

Columbia Trust US Smaller Companies Fund

(0.3082%)

since

2025/06/30

40.

Bruce

(0.2853%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.2788

Latest Release

Date

2025-09-30

EPS Actual

-0.24

EPS Estimate

-0.2763

EPS Difference

0.0363

Surprise Percent

13.1379%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.